Abstract
PD-1 antibody-associated hematological adverse events have been extremely rare in the clinical trials of both nivolumab and pembrolizumab so far. In Hodgkin’s lymphoma (HL), 4/23 patients (17%) reported thrombocytopenia, 1 patient had grade 3 thrombocytopenia from MDS [1].